Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas

International Journal of Cancer

Volumn 123, Issue 9, 2008, Pages 2048-2056

  Marmé, Alexander ^a,b   Zimmermann, Hans Peter ^c   Moldenhauer, Gerhard ^c   Schorpp Kistner, Marina ^c   Müller, Claudia ^c   Keberlein, Olga ^c   Giersch, Antje ^c   Kretschmer, Jürgen ^c   Seib, Brigitte ^c   Spiess, Eberhard ^c   Hunziker, Andreas ^c   Merchán, Faustino ^d   Möller, Peter ^e   Hahn, Uwe ^a   Kurek, Raffael ^b   Marmé, Frederik ^a   Bastert, Gunther ^a   Wallwiener, Diethelm ^b   Ponstingl, Herwig ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF EXTREMADURA   (Spain)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Biomarker; Epigenetic regulation; hMOF

Indexed keywords

GENE PRODUCT; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN DROP1; UNCLASSIFIED DRUG; NERVE PROTEIN; NUCLEAR PROTEIN; SYNE1 PROTEIN, HUMAN;

5' UNTRANSLATED REGION; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CARCINOMA; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; EARLY CANCER; EXON; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY CARCINOMA; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; OVARY CARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNE1 GENE; THYROID CARCINOMA; TWO HYBRID SYSTEM; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA; BREAST TUMOR; FEMALE; GENETICS; NEOPLASM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; NEOPLASMS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; RNA, MESSENGER; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 51649107126     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23763     Document Type: Article

References (46)

1. Liang P, Pardee AB. Analysing differential gene expression in cancer. Nat Rev Cancer 2003;3:869-76.
2. Apel ED, Lewis RM, Grady RM, Sanes JR. Syne-1, a dystrophin- and Klarsicht-related protein associated with synaptic nuclei at the neuromuscular junction. J Biol Chem 2000;275:31986-95.
3. Zhang Q, Skepper JN, Yang F, Davies JD, Hegyi L, Roberts RG, Weissberg PL, Ellis, Juliet A, Shanahan CM. Nesprins: a novel family of spectrin-repeat-containing proteins that localize to the nuclear membrane in multiple tissues. J Cell Sci 2001;114:4485-98.
4. Mislow JM, Holaska JM, Kim MS, Lee KK, Segura-Totten M, Wilson KL, McNally EM. Nesprin-1α self-associates and binds directly to emerin and lamin A in vitro. FEBS Lett 2002;525:135-40.
5. Fan J, Beck KA. A role for the spectrin superfamily member Syne-1 and kinesin II in cytokinesis. J Cell Sci 2004;117:619-29.
6. Cottrell J, Borok E, Horvath T, Nedivi E. CPG2: a brain- and synapse-specific protein that regulates the endocytosis of glutamate receptors. Neuron 2004;44:677-90.
7. Padmakumar VC, Abraham S, Braune S, Noegel AA, Tunggal B, Karakesisoglou I, Korenbaum E. Enaptin, a giant actin-binding protein, is an element of the nuclear membrane and the actin cytoskeleton. Exp Cell Res 2004;295:330-39.
8. Zhang Q, Ragnauth CD, Skepper JN, Worth NF, Warren DT, Roberts RG, Weissberg PL, Ellis JA, Shanahan CM. Nesprin-2 is a multi-isomeric protein that binds lamin and emerin at the nuclear envelope and forms a subcellular network in skeletal muscle. J Cell Sci 2005;118:673-87.
9. Zhang Q, Bethmann C, Worth NF, Davies JD, Wasner C, Feuer A, Ragnauth CD, Yi Q, Mellad JA, Warren DT, Wheeler MA, Ellis JA, et al. Nesprin-1 and -2 are involved in the pathogenesis of Emery-Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet 2007;16:2816-33.
10. Gruenbaum Y, Margalit A, Goldman R, Shumaker D, Wilson K. The nuclear lamina comes of age. Nat Rev Mol Cell Biol 2005;6:21-31.
11. Wilhelmsen K, Ketema M, Hoa T, Sonnenberg A. KASH-domain proteins in nuclear migration, anchorage and other processes. J Cell Sci 2006;119:5021-29.
12. Gough LL, Fan J, Chu S, Winnick S, Beck KA. Golgi localization of Syne-1. Mol Biol Cell 2003;14:2410-24.
13. Dupré N, Gros-Louis F, Chrestian N, Verreault S, Brunet D, de Verteuil D, Brais B, Bouchard JP, Rouleau GA. Clinical and genetic study of autosomal recessive cerebellar ataxia type 1. Ann Neurol 2007;62:93-8.
14. Gros-Louis F, Dupre N, Dion P, Fox MA, Laurent S, Verreault S, Sanes JR, Bouchard JP, Rouleau GA. Mutations in SYNE1 lead to a newly discovered form of autosomal recessive cerebellar ataxia. Nat Genet 2007;39:80-5.
15. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA. Laser capture microdissection. Science 1996;274:998-1001.
16. Kayser S, Watermann I, Rentzsch C, Weinschenk T, Wallwiener D, Gückel B. Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition? J Cancer Res Clin Oncol 2003;129:397-409.
17. Momburg F, Moldenhauer G, Hämmerling G, Möller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47:2883-91.
18. Mechtersheimer G, Staudter M, Majdic O, Dorken B, Moldenhauer G, Möller P. Expression of HLA-A,B,C, beta 2-microglobulin (beta 2m). HLA-DR, -DP, -DQ and of HLA-D-associated invariant chain (Ii) in soft-tissue tumors. Int J Cancer 1990;46:813-23.
19. Albers M, Kranz H, Kober I, Kaiser C, Klink M, Suckow J, Kern R, Koegl M. Automated yeast two-hybrid screening for nuclear receptor-interacting proteins. Mol Cell Proteomics 2005;4:205-13.
20. Wan JS, Sharp SJ, Poirier GMC, Wagaman PC, Chambers J, Pyati J, Hom YL, Galindo JE, Huvar A, Peterson PA, Jackson MR, Erlander MG. Cloning differentially expressed mRNAs. Nat Biotechnol 1996;14:1685-91.
21. Zhang Q, Ragnauth C, Greener M, Shanahan C, Roberts R. The nesprins are giant actin-binding proteins, orthologous to Drosophila melanogaster muscle protein MSP-300. Genomics 2002;80:473-81.
22. Schultz J, Milpetz F, Bork P, Ponting CP. SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci USA 1998;95:5857-64.
23. Mislow JMK, Kim MS, Davis DB, McNally EM. Myne-1, a spectrin repeat transmembrane protein of the myocyte inner nuclear membrane, interacts with lamin A/C. J Cell Sci 2002;115:61-70.
24. Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J, Allis CD, Chait BT, Hess JL, Roeder RG. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 2005;121:873-85.
25. Mendjan S, Taipale M, Kind J, Holz H, Gebhardt P, Schelder M, Vermeulen M, Buscaino A, Duncan K, Mueller J, Wilm M, Stunnenberg HG, et al. Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila. Mol Cell 2006;21:811-23.
26. Nedivi E, Fieldust S, Theill LE, Hevron D. A set of genes expressed in response to light in the adult cerebral cortex and regulated during development. Proc Natl Acad Sci USA 1996;93:2048-53.
27. Huang LW, Garrett AP, Muto MG, Colitti CV, Bell DA, Welch WR, Berkowitz RS, Mok SC. Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum. Hum Pathol 2000;31:367-73.
28. Fujii H, Zhou W, Gabrielson E. Detection of frequent allelic loss of 6q23-q25.2 in microdissected human breast cancer tissues. Genes Chromosomes Cancer 1996;16:35-9.
29. Chappell SA, Walsh T, Walker RA, Shaw JA. Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. Br J Cancer 1997;75:1324-9.
30. Noviello C, Courjal F, Theillet C. Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion. Clin Cancer Res 1996;2:1601-6.
31. Acevedo CM, Henriquez M, Emmert-Buck MR, Chuaqui RF. Loss of heterozygosity on chromosome arms 3p and 6q in microdissected adenocarcinomas of the uterine cervix and adenocarcinoma in situ. Cancer 2002;94:793-802.
32. Gao H, Wang Q, Wang B, Yan C, Wang S, Wang B, Zhu J, Huang C, Fu S. Genescan analysis of non-small cell lung cancer in the long arm of chromosome 6. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002;19:14-16.
33. Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Wiest JS, Fain P, Schwartz AG, You M, Franklin W, Klein C, Gazdar A, et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 2004;75:460-74.
34. Melendez B, Diaz-Uriarte R, Cuadros M, Martinez-Ramirez A, Fernandez-Piqueras J, Dopazo A, Cigudosa JC, Rivas C, Dopazo J, Martinez-Delgado B, Benitez J. Gene expression analysis of chromosomal regions with gain or loss of genetic material detected by comparative genomic hybridization. Genes Chromosomes Cancer 2004;41:353-65.
35. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92.
36. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M, Burton J, Cox TV, Davies R, Down TA, Haefliger C, Horton R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006;38:1378-85.
37. Parrella P, Poeta M, Gallo A, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, Rabitti C, Rinaldi M, et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 2004;10:5349-54.
38. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA, Laird PW. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004;64:3807-13.
39. Wisman GB, Nijhuis ER, Hoque MO, Reesink-Peters N, Koning AJ, Volders HH, Buikema HJ, Boezen HM, Hollema H, Schuuring E, Sidransky D, van der Zee AG. Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer 2006;119:1908-14.
40. O'Doherty AM, Church SW, Russell SE, Nelson J, Hickey I. Methylation status of oestrogen receptor-alpha gene promoter sequences in human ovarian epithelial cell lines. Br J Cancer 2002;86:282-4.
41. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003;2:731-40.
42. Zhang X, Xu R, Zhu B, Yang X, Ding X, Duan S, Xu T, Zhuang Y, Han M. Syne-1 and Syne-2 play crucial roles in myonuclear anchorage and motor neuron innervation. Development 2007;134:901-8.
43. Kim J, Daniel J, Espejo A, Lake A, Krishna M, Xia L, Zhang Y, Bedford MT. Tudor. MBT and chromo domains gauge the degree of lysine methylation. EMBO Rep 2006;7:397-403.
44. Taipale M, Rea S, Richter K, Vilar A, Lichter P, Imhof A, Akhtar A. hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol Cell Biol 2005;25:6798-810.
45. Fraga MF, Ballesta RE, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
46. Pfister S, Rea S, Taipale M, Mendrzyk F, Straub B, Ittrich C, Thuerigen O, Sinn HP, Akhtar A, Lichter P. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer 2008;122:1207-13.